The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.

However, the magnitude of its effects on cytopenias and survival was inferior to that of entolimod: absolute survival improvement reached with HemaMax at LD 50-65 radiation doses was only 20% compared to 40–60% achieved with entolimod at LD 50-75 doses of TBI, and did not reach statistical significance by pre-specified analyses [ 27 , 28 ].

also in 111,027 other papers